Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone857-259-3840
Debt
Current Ratio3.07
Quick Ratio3.07
Price-To-Earnings
Sales & Book Value
Annual Sales$71.64 million
Price / Sales2.23
Price / Cash FlowN/A
Price / Book0.94
Profitability
Net Income$-16,440,000.00
Net Margins-59.74%
Return on Assets-13.65%
Miscellaneous
Employees112
OptionableOptionable
Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions
What is Jounce Therapeutics' stock symbol?
Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."
How were Jounce Therapeutics' earnings last quarter?
Jounce Therapeutics Inc (NASDAQ:JNCE) released its earnings results on Tuesday, November, 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.34) by $0.11. The firm earned $14.53 million during the quarter, compared to analyst estimates of $12.80 million. Jounce Therapeutics had a negative net margin of 59.74% and a negative return on equity of 29.58%. View Jounce Therapeutics' Earnings History.
When is Jounce Therapeutics' next earnings date?
What guidance has Jounce Therapeutics issued on next quarter's earnings?
Jounce Therapeutics issued an update on its FY 2018 earnings guidance on Tuesday, November, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $50-60 million, compared to the consensus revenue estimate of $56.46 million.
What price target have analysts set for JNCE?
6 brokerages have issued 1-year price targets for Jounce Therapeutics' shares. Their forecasts range from $10.00 to $20.00. On average, they expect Jounce Therapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 165.8% from the stock's current price. View Analyst Price Targets for Jounce Therapeutics.
What is the consensus analysts' recommendation for Jounce Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.
Has Jounce Therapeutics been receiving favorable news coverage?
Media coverage about JNCE stock has trended positive on Thursday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Jounce Therapeutics earned a news sentiment score of 2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days.
Are investors shorting Jounce Therapeutics?
Jounce Therapeutics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 685,595 shares, a decrease of 43.9% from the December 14th total of 1,221,600 shares. Based on an average daily trading volume, of 514,155 shares, the days-to-cover ratio is presently 1.3 days. Currently, 4.7% of the shares of the stock are short sold. View Jounce Therapeutics' Current Options Chain.
Who are some of Jounce Therapeutics' key competitors?
Some companies that are related to Jounce Therapeutics include Gritstone Oncology (GRTS), Adaptimmune Therapeutics (ADAP), DBV TECHNOLOGIE/S (DBVT), PDL BioPharma (PDLI), Mesoblast (MESO), Scholar Rock (SRRK), Agenus (AGEN), CASI Pharmaceuticals (CASI), Krystal Biotech (KRYS), Nightstar Therapeutics (NITE), Avrobio (AVRO), Cellular Biomedicine Group (CBMG), Replimune Group (REPL), MeiraGTx (MGTX) and Voyager Therapeutics (VYGR).
Who are Jounce Therapeutics' key executives?
Jounce Therapeutics' management team includes the folowing people:
- Dr. Richard Murray, Pres, CEO & Director (Age 59)
- Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 53)
- Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 58)
- Dr. James P. Allison, Founder
- Dr. Thomas F. Gajewski, Founder
When did Jounce Therapeutics IPO?
(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.
Who are Jounce Therapeutics' major shareholders?
Jounce Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.10%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Celgene Switzerland Llc, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.
Which institutional investors are buying Jounce Therapeutics stock?
JNCE stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc, Hugh M Cole and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.
How do I buy shares of Jounce Therapeutics?
Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jounce Therapeutics' stock price today?
One share of JNCE stock can currently be purchased for approximately $4.89.
How big of a company is Jounce Therapeutics?
Jounce Therapeutics has a market capitalization of $152.38 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe.
What is Jounce Therapeutics' official website?
How can I contact Jounce Therapeutics?
Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.
MarketBeat Community Rating for Jounce Therapeutics (NASDAQ JNCE)
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
